

11 December 2025

Nanosonics' CORIS® registered in Australia, European Union and United Kingdom

- CORIS system achieves key regulatory milestones now included in the Australian Register of Therapeutic Goods (ARTG) and CE and UKCA marks applied for European Union (EU) and United Kingdom (UK), respectively
- Controlled Market Release (CMR) expected to commence in UK, Ireland & Australia from January 2026

Nanosonics Limited (ASX: NAN), a leader in infection prevention solutions, today announces the registrations required to commercialise its innovative endoscope cleaning system, CORIS, in Australia, the EU and the UK.

"These certifications are pivotal regulatory milestones in our commercialisation journey for CORIS and pave the way for the commencement of our planned Controlled Market Release with select hospital partners. We're excited to commence this next phase through our CMR in Australia, the UK and Ireland early in the new year," said Michael Kavanagh, Nanosonics' CEO & President.

"The CMR in the USA is planned to commence upon approval of the first 510(k) regulatory submission for expanded scope indications which is currently under review by the FDA," he concluded.

About the CORIS system

The CORIS system is a novel technology designed to reduce infection risk and enhance patient safety by delivering improved cleaning outcomes for flexible endoscopes, in particular, the complex channels of endoscopes which are prone to biofilm build up. Through an automated mechanism of action, CORIS combines cutting-edge science and engineering with practical usability to address what is recognised as one of the most critical challenges in medical device reprocessing today.

For more information, please contact:

Catherine Strong, Head of Investor Relations and Corporate Communications +61 (0)406 759 268, c.strong@nanosonics.com

Authorised by the Chair of Directors of Nanosonics Limited.

CORIS® is a registered trade mark of Nanosonics Limited.